Figures computed from official regulatory filings — .
Analysttarget 134.62 USD (-0%) · consensus 5/5 · 9 buy · 0 hold · 0 sell
Ownershipinsiders 2.32% · institutions 110.8% · short 7.3% of float
In USD · as of Oct 19, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Apogee Therapeutics, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Apogee Therapeutics, Inc. develops and commercializes biologic therapies for immunological and inflammatory (I&I) diseases for patients and caregivers. The company's pipeline includes products, such as ZUMILOKIBART (APG777), a monoclonal antibody for atopic dermatitis, asthma, and eosinophilic esophagitis; APG990, a monoclonal antibody targeting OX40L; APG808, an antibody targeting IL-4Ra for chronic obstructive pulmonary disease and asthma; APG333, a half-life extended TSLP antibody; APG279, a combination therapy for atopic dermatitis; and APG273 for asthma and COPD. It also provides services related to engineering and optimizing antibodies with improved pharmacokinetics to reduce injection frequency for patients. The company was founded in 2022 and is based in San Francisco, California with an additional office in Waltham, Massachusetts. As of September 3, 2026, Apogee Therapeutics, Inc. operates as a subsidiary of AbbVie Inc.
Market information source · Oct 19, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 19, 2026
Open-market timeline · full history
6 buys131 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Shah Nimish Ptrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| HENDERSON MICHAEL THOMAS | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Dambkowski Carl | Other | n/a (No price was disclosed in the filing) | SEC |
| McKenna Mark C. | Other | n/a (No price was disclosed in the filing) | SEC |
| Fairmount Funds Management LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Dambkowski Carl | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Shah Nimish Ptrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Henderson Jane | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Fairmount Funds Management LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| HENDERSON MICHAEL THOMAS | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JONES WILLIAM A JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Dambkowski Carl | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Henderson Jane | Other | n/a (No price was disclosed in the filing) | SEC |
| Bollinger Lisa | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| HENDERSON MICHAEL THOMAS | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Fox Jennifer A. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Fairmount Funds Management LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Bollinger Lisa | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JONES WILLIAM A JR | Other | n/a (No price was disclosed in the filing) | SEC |
| Fox Jennifer A. | Other | n/a (No price was disclosed in the filing) | SEC |
| Fairmount Funds Management LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| JONES WILLIAM A JR | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Fairmount Funds Management LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Shah Nimish Ptrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| McKenna Mark C. | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |